1. Sensiblu, the second leading pharmaceutical retailer, with almost 1.2 billion lei (EUR266 million) revenue last year, bought 78 Polisano group retail pharmacies at the end of September, so its network grew to 420. The parties did not reveal the value of the deal.
2. Farmacia Tei, a business established by entrepreneur Roxana Maftei more than two decades ago, ended last year with RON119 million revenue and in 2016 started expansion in Bucharest with a new 1,000 square meter store in Dristor. Market leader, Catena, which posted RON1.8 billion revenue last year, too, decided to pursue an expansion strategy, growing to 600 pharmacies in the country. Its owner, Anca Vlad, told ZF she was looking at new acquisitions on the retail segment.
3. Ropharma Brasov, of businessman Mihai Miron, the fifth largest pharmaceutical retailer (RON439 million revenue in 2015) in Romania, merged by absorption with Cristina Farm, Nipan Farm and Farmacia Sedofarm. Ropharma had more than 130 pharmacies last year and Mihai Miron has recently said he expects the business to go up about 10% this year.
4. Polisano Sibiu, the wholesale unit of the group by the same name, early this fall announced it had filed for insolvency. It posted RON527 million revenue in 2015, down 60% on the previous year. Although it cut debt by almost 50% in 2015, and the number of employees shrank by about 200, Polisano was unable to avoid insolvency.
5. French-held pharmaceutical group Sanofi, whose Romanian subsidiary is the second largest pharmaceutical manufacturer in the country after AbbVie and posted RON815 million revenue last year, announced plans to sell its European generic drugs division. The step will affect Zentiva, its pharmaceutical plant in Romania, which will be put up for sale. Zentiva is the leader of the Romanian generic drug market by sales volumes, according to its own website.
6. GlaxoSmithKline (GSK), the seventh leading pharmaceutical company in Romania, which posted RON500 million revenue last year, closed the Europharm pharmaceutical plant in Brasov due to the group’s production overcapacity. GSK started reorganization of its local operations and also decided to sell the wholesale division.
7. The drug market, which Cegedim puts at about RON3 billion, saw growth of 16% in the second quarter compared with the year-ago period. The top companies on this market have changed positions over the past seven years, with AbbVie the current leader, up five positions on the previous year, with 7.8% market share, according to Cegedim. AbbVie’s performance is because of the reimbursement by the National Health Insurance House of the medication (Viekirax) necessary for treating chronic viral hepatitis. AbbVie beat Sanofi, the leader of five years, to the top spot.
8. Swiss-held Novartis, which ranks third on the pharmaceutical market in Romania (RON643 million revenue last year), appointed Alina Culcea (45) as chairperson of the board of the directors of the group’s Romanian operation. Pfizer, fifth leading pharmaceutical company with RON531 million revenue in 2015, made management changes, too, appointing Mirela Iordan, 47, country manager.
9. The methodology to calculate drug prices, enacted on October 26, provides for a 35% drop in the price of drugs whose patent expired, to be implemented in three steps as of April next year. Pharmaceutical manufacturer and patient associations criticized the step, saying some drugs will no longer be available on the market if their price becomes too low. One of the problems in Romania’s healthcare system is the shortage of certain drugs, so patients have to go buy them themselves to receive necessary treatment in hospitals.
10. Two new names held the position of health minister in the past year. After Nicolae Baniciou resigned in November 2015, following the Colectiv club fire, Patriciu Achimas-Cadariu replaced him, but only lasted six months on the job and had to resign when the diluted hospital disinfectant scandal hit broke out. Economist Vlad Voiculescu took the position of health minister this May for an equally short term, as the December 11 elections will most likely bring a new government.
(English version by Loredana Fratila-Cristescu)